Anupama Kaul, MD
Pulmonary Disease · Hot Springs, ARNPI 1710938097
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations.
Across 288 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$528
- Boehringer Ingelheim$474
- Grifols USA, LLC$378
- Jazz Pharmaceuticals Inc.$344
- Mylan Specialty L.p.$333
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,24296%
- Education$2154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 82 | $1,185 |
| AstraZeneca | 33 | $528 |
| Boehringer Ingelheim | 24 | $474 |
| Grifols USA, LLC | 19 | $378 |
| Jazz Pharmaceuticals Inc. | 13 | $344 |
| Mylan Specialty L.p. | 19 | $333 |
| Insmed, Inc. | 12 | $236 |
| Actelion Pharmaceuticals US, Inc. | 8 | $221 |
| Harmony Biosciences LLC | 11 | $194 |
| Mallinckrodt Hospital Products Inc. | 5 | $191 |
| Inspire Medical Systems, Inc. | 3 | $184 |
| Sanofi | 9 | $179 |
| Philips North America LLC | 9 | $174 |
| Verona Pharma, Inc. | 6 | $170 |
| Regeneron Healthcare Solutions, Inc. | 6 | $122 |
| Mallinckrodt Enterprises LLC | 5 | $88 |
| Viatris Specialty LLC | 5 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $77 |
| Baxter Healthcare | 4 | $70 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| Advanced Respiratory, Inc | 2 | $37 |
| ZOLL Respicardia, Inc. | 1 | $27 |
| United Therapeutics Corporation | 1 | $26 |
| Merck | 1 | $24 |
| Fisher & Paykel Healthcare Inc | 1 | $16 |
| Electromed, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,457 in reported general payments places this provider in the 65th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 37 | $543,665 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 16 | $187,476 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 149 | $111,196 |
| Breo ElliptaFluticasone/Vilanterol | 133 | $55,349 |
| Spiriva RespimatTiotropium Bromide | 31 | $24,443 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $15,121 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $15,105 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $12,456 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $9,343 |
| Spiriva HandihalerTiotropium Bromide | 11 | $8,225 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $7,943 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $5,665 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 233 | $5,521 |
| BreynaBudesonide/Formoterol Fumarate | 22 | $4,753 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $4,669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $474 | $580,56494 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,185 | $194,025350 claims |
| Grifols USA, LLCProlastin C | $378 | $187,47616 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $528 | $28,72972 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Hot Springs
- Jessica TreatHot Springs$13K
- Albert ChinnHot Springs$7K
- Jovan GayleHot Springs$5K
- Jarmil PetersHot Springs$3K
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Arturo MeadeFort Smith$67K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.